Sativex
Sativex represents the first plant-derived cannabinoid medicine approved by a medicines regulator, a distinction that underscores its pioneering role in legitimising cannabis-based therapeutics.
OPINION
The industry's 38 tonnes of unsold inventory isn't just an economic problem. It's karma.
Cann Group
The debt forgiveness of $54.7 million represents an 81% reduction in the company's debt and will increase Cann Group's net assets by approximately $60 million.
tga
The contrast between Germany's success and Australia's stagnation raises a fundamental question: what structural differences enable one country to achieve rapid market transformation while another remains locked in gatekeeping and corporate control?
tga
As health bodies call for crackdown on rogue operators, affordability crisis goes unaddressed.
tga
The Reviewing the Safety and Regulatory Oversight of Unapproved Medicinal Cannabis Products consultation commenced on 11 August 2025 and will close on 7 October.
Ecofibre Limited was an Australian biotechnology company focused on hemp-derived products and technologies. The company listed on the ASX on March 29, 2019, through an IPO that raised $20 million at $1 per share, giving it a market capitalization of $309 million on listing¹. The business was headed by rich-lister
Sativex represents the first plant-derived cannabinoid medicine approved by a medicines regulator, a distinction that underscores its pioneering role in legitimising cannabis-based therapeutics.
The debt forgiveness of $54.7 million represents an 81% reduction in the company's debt and will increase Cann Group's net assets by approximately $60 million.
The Reviewing the Safety and Regulatory Oversight of Unapproved Medicinal Cannabis Products consultation commenced on 11 August 2025 and will close on 7 October.
The consultation does not address home cultivation as a potential solution to affordability concerns, despite this approach being adopted in countries like Canada and several European nations.
You know you want to..
The prohibition creates a two-tiered system where access depends on wealth. Canadian patients can grow unlimited plants based on prescription. Low-income patients aren't excluded due to cost barriers.
The consultation does not address home cultivation as a potential solution to affordability concerns, despite this approach being adopted in countries like Canada and several European nations.
A groundbreaking study has provided the first definitive proof that legal medical cannabis can be a deadly source of infection for vulnerable patients.
The research suggests that cannabis cultivators face a trade-off when growing purple varieties.
Australia's approach to road safety offers valuable lessons for drug policy.
This duality—strict law, informal leniency—offers a glimpse into what cannabis may become in Thailand: legal enough to use, risky enough to sensationalise.
Thailand’s Ministry of Public Health estimates 23,000 alcohol-related deaths per year, costing over 1% of GDP. Contrast to cannabis...
“Australia’s debate on marijuana legalisation continues to evolve. With nearly half of Australians now in favour, the national mood has shifted significantly over the past decade.”
The use of standard web forms and international platforms for collecting such sensitive data raises questions about whether providers are taking adequate steps to protect patient information.
Cann Group requested that the ASX grant a trading halt pending an announcement to be made by the Company, to the market, regarding the Company’s capital raising activities.
The vision is simple: a cannabis sector structured to prioritize small-scale operators.
All I want for Christmas is the right to grow, Not paying through the nose for what I sow. While others tend their garden spots with care, My medicine's locked behind red tape and prayer. These clinic fees are robbing us outright, With prices soaring to a ridiculous